LGR6 高表达是食管癌的一个不良预后因素。

High expression of LGR6 is a poor prognostic factor in esophageal carcinoma.

机构信息

Department of Surgery, North Alps Medical Center Azumi Hospital, Ikeda, Japan.

Department of Laboratory Medicine, Shinshu University School of Medicine, Matsumoto, Japan.

出版信息

Pathol Res Pract. 2023 Feb;242:154312. doi: 10.1016/j.prp.2023.154312. Epub 2023 Jan 16.

DOI:10.1016/j.prp.2023.154312

PMID:36701848

Abstract

BACKGROUND

Leucine-rich repeat-containing G-protein-coupled receptor 6 (LGR6) promotes carcinogenesis and progression in some cancer types. However, there are few reports of LGR6 expression in esophageal squamous cell carcinoma (ESCC). LGR6 expression and clinicopathological features in ESCC were investigated by RNAscope, a highly sensitive RNA in situ hybridization method.

METHODS

Appropriate tumors were selected from 41 cases of ESCC from which tissue microarrays were generated, and LGR6 expression was identified by RNAscope.

RESULTS

Thirty-seven patients had LGR6 expression. High LGR6 expression was observed in 17 cases and low LGR6 expression in 24 cases. LGR6 expression was significantly higher in high histological grade ESCC than in low histological grade ESCC (P = 0.0023). ESCC patients who received neoadjuvant chemotherapy had significantly higher LGR6 expression than those without neoadjuvant chemotherapy (P = 0.0109). Furthermore, high LGR6 expression showed a poorer prognosis than low LGR6 expression (log-rank test, P = 0.0365).

CONCLUSIONS

LGR6 may be a prognostic factor and a potential new therapeutic target in ESCC.

摘要

背景

富含亮氨酸重复序列的 G 蛋白偶联受体 6（LGR6）在某些癌症类型中促进癌症的发生和进展。然而，关于 LGR6 在食管鳞状细胞癌（ESCC）中的表达的报道很少。本研究通过高灵敏度的 RNA 原位杂交方法 RNAscope 研究了 LGR6 在 ESCC 中的表达和临床病理特征。

方法

从生成组织微阵列的 41 例 ESCC 中选择了适当的肿瘤，并通过 RNAscope 鉴定了 LGR6 的表达。

结果

37 例患者有 LGR6 表达。高组织学分级的 ESCC 中高 LGR6 表达的比例高于低组织学分级的 ESCC（P=0.0023）。接受新辅助化疗的 ESCC 患者的 LGR6 表达明显高于未接受新辅助化疗的患者（P=0.0109）。此外，高 LGR6 表达的患者预后较 LGR6 低表达的患者差（对数秩检验，P=0.0365）。